Navigation Links
Nexavar in Medical News

Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer

WAYNE, N.J. and EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar(R) (sorafenib) tablets...

Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer

Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with he...

Scientists Learn How Cancer Drugs Cause Hypertension

...-third of cancer patients who take drugs to block the formation of blood vessels that feed tumors. "Anti-angiogenesis drugs like Avastin, Sutent or nexavar inhibit an important substance called vascular endothelial growth factor [VEGF] that stimulates the creation of new vessels that support malignant gro...

Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer

...ree survival was extended in patients treated with nexavar and capecitabine compared to patients receiving ca...yx and Bayer are evaluating various strategies for nexavar in breast cancer. nexavar is already benefiting patients worldwide with live...

Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018

...geted agents such as Pfizer's figitumumab as a first-line treatment for advanced NSCLC as well as the emergence of AstraZeneca's Zactima, Bayer/Onyx's nexavar and Boehringer Ingelheim's Tovok as second-line and subsequent-line options. Additionally, from 2013 to 2018, Roche/Chugai's Avastin -- which is alrea...

Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer

...m the Phase 3 SHARP trial, which demonstrated that nexavar significantly extended overall survival in patient...lue=0.0006). Based on the strength of these data, nexavar was approved for the treatment of patients with un...ed States and in Europe for the treatment of HCC. nexavar is currently approved in more than 70 countries fo...

Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer

...95 percent of all liver cancer cases in Japan(1). nexavar is also currently available in Japan as an approve...d no prior systemic therapy. The study found that nexavar improved overall survival in patients with HCC by ...p=0.0006) versus placebo. Based on SHARP results, nexavar is currently approved in more than 70 countries fo...

Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference

...cals, Inc., is developing and marketing Nexavar(R), a small molecule drug. nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, nexavar is being investigated in several ongoing trials in a variety of tumor types...

Onyx Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference

...cals, Inc., is developing and marketing Nexavar(R), a small molecule drug. nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, nexavar is being investigated in several ongoing trials in non-small cell lung canc...

Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results

...ty with GAAP Earnings Per Share of $0.03 2008 nexavar Net Sales of $678 Million Represents 82% Growth Ov...iation of GAAP to Non-GAAP Net Income. Global nexavar net sales grew 82% to $677.8 million for the full ...tial of the company, creating a rich pipeline with nexavar and beginning to shape a diversified portfolio bey...
Nexavar in Medical Technology

Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint

WAYNE, N.J. and EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that a Phase 3 trial evaluating Nexavar(R) (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma was s...

Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer

WAYNE, N.J. and EMERYVILLE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the companies have begun enrolling patients in the STORM Sorafenib as Adjuvant Treatment in the Prevention of Recurrence ...

New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting

WAYNE, N.J. and EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the presentation of new clinical data from the early clinical trials in the development program for Nexavar(R) (sorafenib)...

Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007

Leverkusen, Germany, May 31, 2007- Results from various clinical studies including a pivotal Phase III trial in patients with advanced hepatocellular carcinoma, or primary liver cancer with Nexavar (sorafenib) tablets will be presented at the Annual Meeting of the American Society of Clinical Onco...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

...nitor, no other therapy has been studied in a Phase III trial in this patient population where there is an important unmet medical need(1). Sutent and nexavar are commonly used as initial treatments for advanced RCC(2). The approval is based on data that showed Afinitor, when compared with placebo, more...

Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer

...ykerb, Pfizer's Sutent and Bayer Healthcare/Onyx's nexavar for their approved indications in cancer, which in...over Tykerb and six of the MCOs that fail to cover nexavar cite the ability to negotiate a more favorable con...e prescription drug plans carry neither Sutent nor nexavar and one quarter fails to cover Avastin." Targete...

The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer

... - nexavar is First Approved Systemic Therapy to Treat the Di...th Nexavar. Based on the strength of these data, nexavar was approved for HCC by the European Agency for th...udy reflects a new systemic standard of care using nexavar in the first-line management of liver cancer." "...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

...st-line therapy. -- Hepatocellular cancer. In April 2008, HGS announced plans to initiate a randomized trial of HGS-ETR1 in combination with nexavar (sorafenib) in patients with advanced hepatocellular cancer. HGS-ETR1 is the most advanced of any product in development that targets the TRAIL ...

RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer

...00 F: +1 732 817 1834 Veronique Boissonnas Ruder Finn P: +1 212 593 6396 F: +1 646 792 4415 **Sutent is a registered trademark of Pfizer Inc. nexavar is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc. ...

Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study

...imary liver cancer versus those receiving placebo. nexavar also significantly improved time to progression in... randomized trial evaluated efficacy and safety of nexavar versus placebo in 226 Asian patients with advanced...y RECIST criteria and safety in patients receiving nexavar versus placebo. Median overall survival was 6.5 mo...
Nexavar in Biological News

Researchers shed light on mechanism of action used by anti-cancer drug

...and other proteins. The findings were published online in the journal Molecular and Cellular Biology on June 4. According to Grant, sorafenib, or nexavar which is manufactured by Bayer Pharmaceuticals, has recently been approved for the treatment of patients with renal cell cancer, the most common form ...
Nexavar in Biological Technology

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

WAYNE, N.J. and EMERYVILLE, Calif., May 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that more than 65 studies evaluating the use of Nexavar(R) (sorafenib) tablets will be presented at the 2009 American Society...

Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting

WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced more than 40 data presentations at the 2008 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the ...

Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results

EMERYVILLE, Calif., Feb. 19 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it will webcast a teleconference with management to provide an update on Nexavar(R) (sorafenib) tablets, as well as to discuss fourth quarter and full year 2007 financial resu...

Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar

EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it will host a teleconference and webcast on Monday, April 27, 2009, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to provide an update on Nexavar(R) (sorafenib) tablets. ...

OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance

...ll carcinoma had metastasized to his lungs; by 2006, he was in the advanced stages of his disease. Reeder's physicians began treating him with nexavar , an oral multiple kinase inhibitor that has been shown to significantly slow the spread of advanced kidney cancer in a majority of patients. By fill...

Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

...jected to steadily increase between the period 2010 and 2015, as stated by the new market research report. New generation kinase inhibitor drugs like nexavar are forecast to witness robust growth over the period 2006 through 2015. Leading players operating in the marketplace include Amgen Inc, Novart...

Onyx Pharmaceuticals Files Complaint Against Bayer Corporation

...cals, Inc., is developing and marketing Nexavar(R), a small molecule drug. nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, nexavar is being investigated in several ongoing trials in a variety of tumor types...

Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast

...cals, Inc., is developing and marketing Nexavar(R), a small molecule drug. nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, nexavar is being investigated in several ongoing trials in non-small cell lung canc...

Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference

...cals, Inc., is developing and marketing Nexavar(R), a small molecule drug. nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, nexavar is being investigated in several ongoing trials in non-small cell lung canc...

Onyx Pharmaceuticals to Present at the 27th Annual JPMorgan Healthcare Conference

...cals, Inc., is developing and marketing Nexavar(R), a small molecule drug. nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, nexavar is being investigated in several ongoing trials in non-small cell lung canc...
Other Tags
(Date:8/31/2015)... Knoxville, TN (PRWEB) , ... September 01, 2015 , ... ... function and other clinically relevant measures for physical therapy patients. The Registry is being ... President of FOTO, Inc. stated "We are happy to be selected to contribute FOTO ...
(Date:8/31/2015)... ... 31, 2015 , ... Cosmetic Town Journal is an online ... have a successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients ... ready to help. , It is clear that the Cosmetic Town aesthetic surgery ...
(Date:8/31/2015)... ... ... to undergoing a hair transplant, most patients have donor hair moved from one part of ... on top of the scalp, as well as filling in areas missing hair, is a ... areas of their head. , What about patients who have a limited, or even depleted, ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law firm ... Scott has been nominated by his peers to earn a “Leading Lawyers” distinction. ... of attorneys in the state of Illinois. The nomination process is based on statewide ...
(Date:8/31/2015)... ... August 31, 2015 , ... CareSource, a nonprofit Ohio-based ... In this capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate ... programs that have contributed to the company’s rapid growth. As the CareSource business ...
Breaking Medicine News(10 mins):Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
Other Contents